Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00044
|
|||||
| Drug Name |
Topotecan
|
|||||
| Synonyms |
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamptamine; Hycamptin; Hycamtamine; Hycamtin; Hycamtin (TN); SK&F-104864-A; SKF 104864; SKF-104864-A; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan Monohydrochloride, (S)-Isomer; Topotecan [INN:BAN]; Topotecan lactone; Topotecane; Topotecane [INN-French]; Topotecanum; Topotecanum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Ovarian cancer [ICD11: 2C73] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H23N3O5
|
|||||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
|
|||||
| InChI |
InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
|
|||||
| InChIKey |
UCFGDBYHRUNTLO-QHCPKHFHSA-N
|
|||||
| CAS Number |
CAS 119413-54-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 421.4 | Topological Polar Surface Area | 103 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103170619
, 103922004
, 103942242
, 104321416
, 11409161
, 11459078
, 11461196
, 117586312
, 124878927
, 124878928
, 126631363
, 126682466
, 129347572
, 13340
, 134337938
, 135026276
, 135610141
, 136342520
, 136376449
, 137007926
, 137275799
, 142090317
, 144220376
, 14807035
, 14904851
, 152106211
, 152198470
, 160660968
, 160964365
, 24769902
, 43118056
, 46505204
, 47348955
, 47499101
, 47572929
, 48242924
, 50028360
, 50123362
, 53790588
, 56311903
, 57314070
, 581639
, 606579
, 78527173
, 7890901
, 7980817
, 8187013
, 92309036
, 92710943
, 96025302
|
|||||
| ChEBI ID |
CHEBI:63632
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [3] | ||
| MATE2 | Transporter Info | Multidrug and toxin extrusion protein 2 | Substrate | [3] | ||
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [6] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | BCRP | Transporter Info | Km = 213 microM | Madin-Darby canine kidney cells (MDCKII)-BCRP | [6] | |
| MATE1 | Transporter Info | Km = 70 microM | Human embryonic kidney cells (HEK293)-MATE1 | [3] | ||
| MATE2 | Transporter Info | Km = 60 microM | Human embryonic kidney cells (HEK293)-MATE2K | [3] | ||
| MRP4 | Transporter Info | Km = 1.66 microM | Human liver cancer cells (HepG2)-MRP4 | [5] | ||
| P-GP | Transporter Info | Km = 78.3 microM | Human enterocyte-like 2 cells (Caco-2)-MDR1 | [6] | ||
| P-GP | Transporter Info | Km = 102 microM | Madin-Darby canine kidney cells (MDCKII)-MDR1 | [6] | ||
| References | ||||||
| 1 | Topotecan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8. | |||||
| 3 | Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 5 | Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18. | |||||
| 6 | Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.